表紙
市場調查報告書
商品編碼
1035547

非酒精性脂肪性肝炎:基於流行病學的當前市場規模和預測 (2020年∼2030年),各企業的新藥價格策略,交易價值的評估,r-NPV,管道醫藥品分析 (2021年下半年)

Non-Alcoholic Steatohepatitis - Epidemiology Based Current (2020) and Forecasted (Till 2030) Market Values, Competitor New Drugs Pricing Strategies, Deal worth Assessments, r-NPV and Pipeline Drugs Analytics H2 2021

出版日期: | 出版商: GervanoRA Data Services LLP | 英文 180 Pages | 商品交期: 3-5個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

本報告提供全球非酒精性脂肪性肝炎的治療藥的市場相關分析,彙整疾病概要和市場概要,基於流行病學的市場規模預測,新企業的市場佔有率和價格策略,風險調整後的淨現值 (r-NPV),與主要的管道分子的評估交叉比較 (HSD·各地區·各給藥途徑·各類藥物·各作用機制·目標分子·各分子類型),未滿足需求與市場機會,專利比較分析,近來的資本交易趨勢等資訊。

目錄

第1章 簡介

第2章 摘要整理

第3章 非酒精性脂肪性肝炎的概要與流行病學研究

第4章 非酒精性脂肪性肝炎:目前市場規模與預測 (2020年∼2030年)

第5章 管道比較分析與基準:概況

第6章 非酒精性脂肪性肝炎的競爭空間的交易活動

第7章 非酒精性脂肪性肝炎的管道醫藥品:專利比較分析

第8章 風險調整後的淨現值 (r-NPV)的分析

第9章 競爭機會的評估

第10章 市場動態

第11章 各企業的新藥價格策略

目錄
Product Code: GERPH212207

GervanoRA's pipeline analysis and opportunity assessment report "Non-Alcoholic Steatohepatitis - Epidemiology Based Current (2020) and Forecasted (Till 2030) Market Values, Competitor New Drugs Pricing Strategies, Deal worth Assessments, r-NPV and Pipeline Drugs Analytics H2 2021" analysed and assessed Non-Alcoholic Steatohepatitis pipeline molecules for the opportunities in the competitive space by covering all the pipeline molecules in different stages of development and all the companies which are actively involved in Non-Alcoholic Steatohepatitis drugs industry.

The report has been divided into segments like Disease Overview, Market Overview, Pipeline Analytics to provide in depth insights about the market dynamics and ongoing R&D in the Non-Alcoholic Steatohepatitis area. The report provides detailed insights about all the pipeline molecules in different stages of development and all the companies which are actively involved in Non-Alcoholic Steatohepatitis drugs industry. To provide systematic pipeline analytics, we have segregated total pipeline molecules into different segments like Pipeline Analytics by Stage of development, Pipeline Analytics by Route of Administration, Pipeline Analytics by Geography, Pipeline Analytics by Mechanism of Action, Pipeline Analytics by Drug Class, Pipeline Analytics by Molecule Type, Pipeline Analytics by Molecule Target and Pipeline Analytics by Company Type.

The report delivers an in-depth understanding of the Non-Alcoholic Steatohepatitis historical and forecasted epidemiology based market trends Worldwide, the United States, EU9 (Poland, Russia, Switzerland, Sweden, Italy, Germany, Austria, France, and United Kingdom) and China. A detailed analytics on the Current Non-Alcoholic Steatohepatitis Market (2020) and the Forecasted Non-Alcoholic Steatohepatitis Market until the year 2030 for the regions have been provided.

Growth opportunities in the report have been provided by performing a competitive and comparative analysis on the Emerging companies in the domain based on In-Licensing opportunities, Out-Licensing opportunities, Corporate Partnering opportunities and funding opportunities. The report even aimed to conduct the Risk-Adjusted Net Present Value (RNPV) Analysis with its Excel based r-NPV analysis model to help companies in licensing negotiations, technology valuations and pipeline asset valuation and establishing the value for licensing deal. It also aims to provide the sales potential of the drugs along with the new drugs pricing and pricing strategies.

Report is more focused to provide competitive opportunities by assessing and providing in-depth analytics on:

  • Epidemiological Studies - Historical Trends and Probabilistic Epidemiology Forecast
  • Epidemiology Based Market Estimations - Current Market Value and Market Forecast
  • Plotting of the Anticipated Market Share for the New Entrants
  • Pricing Strategies of New Entrants Supported Through KOL Insights
  • Risk-Adjusted Net Present Value (RNPV) Analysis
  • Comparative Pipeline Insights and Benchmarking Snapshots by HSD, Geography, RoA, Drug Class, MoA, Molecule Target, Molecule Type
  • Unmet Needs and Opportunities
  • Comparative Patent Analytics of Non-Alcoholic Steatohepatitis Pipeline Drugs
  • Competitive Opportunity Assessments of the Active Players in the Non-Alcoholic Steatohepatitis Therapeutic Space by Partnering, Licensing and Funding Opportunities
  • Deals Activities of Non-Alcoholic Steatohepatitis Therapeutic Space

Report helps clients to refine the commercial opportunities from the existing treatment armamentarium to pipeline assets, deals, and deal comparables. Even it helps in identifying the most relevant actors in the field for partnering deals.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

CHAPTER 2: EXECUTIVE SUMMARY

CHAPTER 3: NON-ALCOHOLIC STEATOHEPATITIS OVERVIEW AND EPIDEMIOLOGICAL STUDIES

CHAPTER 4: NON-ALCOHOLIC STEATOHEPATITIS CURRENT MARKET VALUE AND FORECAST 2020 - 2030

CHAPTER 5: COMPARATIVE PIPELINE INSIGHTS AND BENCHMARKING SNAPSHOTS

CHAPTER 6: DEALS ACTIVITIES OF NON-ALCOHOLIC STEATOHEPATITIS COMPETITIVE SPACE

CHAPTER 7: COMPARATIVE PATENT ANALYTICS OF NON-ALCOHOLIC STEATOHEPATITIS PIPELINE DRUGS

CHAPTER 8: RISK-ADJUSTED NET PRESENT VALUE (R-NPV) ANALYSIS

CHAPTER 9: COMPETITIVE OPPORTUNITY ASSESSMENTS

CHAPTER 10: MARKET DYNAMICS

CHAPTER 11: COMPETITOR NEW DRUGS PRICING STRATEGIES

LIST OF TABLES

(COMPLETE LIST CAN BE FOUND IN FULL LENGTH REPORT)

  • TABLE 01: REPORT HIGHLIGHTS IN NUMERICALS
  • TABLE 02: WORLDWIDE EPIDEMIOLOGY INSIGHTS OF NON-ALCOHOLIC STEATOHEPATITIS
  • TABLE 03: GLOBAL NON-ALCOHOLIC STEATOHEPATITIS EPIDEMIOLOGY (2020), FORECAST (2021-2030)
  • TABLE 04: US NON-ALCOHOLIC STEATOHEPATITIS EPIDEMIOLOGY (2020), FORECAST (2021-2030)
  • TABLE 05: UK NON-ALCOHOLIC STEATOHEPATITIS EPIDEMIOLOGY (2020), FORECAST (2021-2030)
  • TABLE 06: LIST OF NEW ENTRANTS CONSIDERED FOR MARKET ESTIMATIONS
  • TABLE 07: NON-ALCOHOLIC STEATOHEPATITIS GLOBAL CURRENT MARKET (2020), FORECAST (2021-2030)
  • TABLE 08: NON-ALCOHOLIC STEATOHEPATITIS US CURRENT MARKET (2020), FORECAST (2021-2030)
  • TABLE 09: COMPARISON OF NON-ALCOHOLIC STEATOHEPATITIS MARKET VALUES GLOBAL VERSUS US (2020-2030)(M$)
  • TABLE 10: PIPELINE ASSETS IN NON-ALCOHOLIC STEATOHEPATITIS DRUG PIPELINE
  • TABLE 11: SPECIAL REGULATORY ALLOWANCES GRANTED FOR NON-ALCOHOLIC STEATOHEPATITIS PIPELINE DRUGS
  • TABLE 12: NON-ALCOHOLIC STEATOHEPATITIS PIPELINE ANALYTICS BY ROUTE OF ADMINISTRATION
  • TABLE 13: NON-ALCOHOLIC STEATOHEPATITIS PIPELINE ANALYTICS BY DRUG CLASS
  • TABLE 14: NON-ALCOHOLIC STEATOHEPATITIS PIPELINE ANALYTICS BY MECHANISM OF ACTION
  • TABLE 15: NON-ALCOHOLIC STEATOHEPATITIS PIPELINE ANALYTICS BY MOLECULE TYPE
  • TABLE 16: MAJOR MERGERS AND ACQUISITIONS IN NON-ALCOHOLIC STEATOHEPATITIS THERAPEUTIC AREA
  • TABLE 17: MAJOR COLLABORATION AGREEMENTS IN NON-ALCOHOLIC STEATOHEPATITIS THERAPEUTIC AREA
  • TABLE 18: MAJOR LICENSING AGREEMENTS IN NON-ALCOHOLIC STEATOHEPATITIS THERAPEUTIC AREA
  • TABLE 19: MAJOR FINANCING AGREEMENTS IN NON-ALCOHOLIC STEATOHEPATITIS THERAPEUTIC AREA
  • TABLE 20: MAJOR TERMINATION AND SETTLEMENT AGREEMENTS IN NON-ALCOHOLIC STEATOHEPATITIS THERAPEUTIC AREA
  • TABLE 21: COMPANIES LOOKING FOR CORPORATE PARTNERING, LICENSING, FUNDING OPPORTUNITIES
  • TABLE 22: ESTIMATED R&D INVESTMENTS OF NEW ENTRANTS

LIST OF FIGURES

(COMPLETE LIST CAN BE FOUND IN FULL LENGTH REPORT)

  • FIGURE 01: NON-ALCOHOLIC STEATOHEPATITIS FORECASTED PREVALENCE & INCIDENCE OF US, EUROPE AND CHINA, 2020 V/S 2030
  • FIGURE 02: GLOBAL NON-ALCOHOLIC STEATOHEPATITIS POPULATION (2020) FORECAST (2021-2030)
  • FIGURE 03: US NON-ALCOHOLIC STEATOHEPATITIS POPULATION (2020) FORECAST (2021-2030)
  • FIGURE 04: GLOBAL NON-ALCOHOLIC STEATOHEPATITIS MARKET CURRENT (2020) AND FORECAST (2021-2030)
  • FIGURE 05: US CURRENT (2020) NON-ALCOHOLIC STEATOHEPATITIS MARKET VALUE COMPARED WITH GLOBAL MARKET (M$)
  • FIGURE 06: YEAR BY YEAR COMPARISON OF NON-ALCOHOLIC STEATOHEPATITIS MARKET VALUES GLOBAL VS USA (2020 - 2030) (M$)
  • FIGURE 07: NON-ALCOHOLIC STEATOHEPATITIS PIPELINE DRUGS ANALYTICS
  • FIGURE 08: NON-ALCOHOLIC STEATOHEPATITIS PIPELINE DRUGS ANALYTICS BY HSD
  • FIGURE 09: NON-ALCOHOLIC STEATOHEPATITIS PIPELINE ANALYTICS BY ROA
  • FIGURE 10: NON-ALCOHOLIC STEATOHEPATITIS PIPELINE ANALYTICS BY DRUG CLASS
  • FIGURE 11: NON-ALCOHOLIC STEATOHEPATITIS PIPELINE ANALYTICS BY DRUG CLASS VERSUS HSD
  • FIGURE 12: NON-ALCOHOLIC STEATOHEPATITIS PIPELINE ANALYTICS BY MECHANISM OF ACTION
  • FIGURE 13: NON-ALCOHOLIC STEATOHEPATITIS PIPELINE ANALYTICS BY MOLECULE TYPE
  • FIGURE 14: NON-ALCOHOLIC STEATOHEPATITIS PIPELINE ANALYTICS BY COMPANY TYPE
  • FIGURE 15: NON-ALCOHOLIC STEATOHEPATITIS DEALS ANALYTICS BY DEAL TYPE